Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 379 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Elizabeth Yeu Lin sold 379 shares of the stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $68.71, for a total value of $26,041.09. Following the completion of the transaction, the insider directly owned 23,698 shares of the company’s stock, valued at $1,628,289.58. This represents a 1.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Thursday, March 19th, Elizabeth Yeu Lin sold 390 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $67.00, for a total value of $26,130.00.
• On Tuesday, March 17th, Elizabeth Yeu Lin sold 375 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $69.42, for a total value of $26,032.50.

Tarsus Pharmaceuticals Stock Down 0.6%

Tarsus Pharmaceuticals stock traded down $0.38 on Friday, hitting $66.37. 45,653 shares of the stock traded hands, compared to its average volume of 585,032. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.21. The firm has a market cap of $2.82 billion, a P/E ratio of -41.02 and a beta of 0.55. The business’s fifty day simple moving average is $69.36 and its 200 day simple moving average is $70.18. Tarsus Pharmaceuticals, Inc. has a 1 year low of $38.51 and a 1 year high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The business had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. As a group, sell-side analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Key Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published tighter quarterly and FY‑2026 EPS forecasts (smaller expected losses vs. consensus), which supports a more constructive growth/recovery thesis for the stock. Read More.
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s upgrade improves outlook but does not represent unanimous conviction across all analysts. Read More.
• Neutral Sentiment: Company fundamentals: most recent quarter showed a slight EPS miss (reported ($0.20) vs. ($0.19) estimate) but revenue beat, leaving fundamentals mixed and dependent on future trial/launch catalysts. Read More.
• Neutral Sentiment: High institutional ownership (~90%) is a double‑edged factor — it stabilizes float but means large holders can move the stock if they adjust positions. Read More.
• Negative Sentiment: Significant insider selling disclosed in multiple Form 4s between Mar 16–19: CEO Bobak Azamian sold ~10.9k–12.0k shares across several days (prices ~ $67–$69), director William J. Link sold 12,500 shares (~$68.79), and several other senior officers also reduced stakes — these large, clustered sales can create immediate downward pressure and raise questions about near‑term liquidity needs or portfolio rebalancing. Read More.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Tarsus Pharmaceuticals by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock valued at $1,137,000 after buying an additional 1,217 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Tarsus Pharmaceuticals by 2.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock valued at $3,659,000 after acquiring an additional 1,394 shares during the period. Jane Street Group LLC lifted its stake in Tarsus Pharmaceuticals by 105.8% during the 1st quarter. Jane Street Group LLC now owns 10,456 shares of the company’s stock valued at $537,000 after acquiring an additional 190,000 shares during the period. Envestnet Asset Management Inc. boosted its holdings in shares of Tarsus Pharmaceuticals by 15.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 10,356 shares of the company’s stock valued at $420,000 after acquiring an additional 1,418 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Tarsus Pharmaceuticals by 8.0% in the second quarter. Geode Capital Management LLC now owns 934,420 shares of the company’s stock worth $37,859,000 after acquiring an additional 68,986 shares during the period. 90.01% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on TARS. Barclays started coverage on shares of Tarsus Pharmaceuticals in a report on Monday, December 8th. They set an “overweight” rating and a $100.00 target price for the company. The Goldman Sachs Group restated a “neutral” rating and issued a $68.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Lifesci Capital upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Monday. Guggenheim boosted their target price on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Finally, Zacks Research downgraded Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.83.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.